This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Wednesday's Health Winners & Losers

Boston Scientific (BSX - Get Report) rose 3% to $17.23 after the company said 5,000 patients have now been treated with its Precision Spinal Cord Stimulation System, a rechargeable shocking device to treat chronic pain. The company is slated to report its quarterly earnings on Thursday.

Bovie Medical's (BVX - Get Report) shares gained ground after the company announced it received Food and Drug Administration marketing approval for a suture-removal device for human, as well as animal, medical procedures. Shares were up 3.8% to $8.50.

Shares of DOV Pharmaceutical (DOVP) rose on positive results of an early trial on its experimental painkiller bicifadine. The drug didn't show signals of possibly causing cancer in rats or mice over two years. "This timeframe is accepted as analogous to administering the drug over a lifetime in humans," the company said in a press release. Shares of DOV were up 4.3% to $1.96.

Alnylam Pharmaceuticals' (ALNY - Get Report) shares fell 1.6% to $12.40 after the company reported a wider-than-expected net loss in the second quarter.

The company lost $9.9 million, or 31 cents a share in the quarter, including $1.6 million, or 5 cents a share, in stock-based compensation expenses, compared with a loss of $11.1 million, or 54 cents a share, a year ago. Analysts were expecting the company to lose 28 cents a share. Revenue in the second quarter exceeded expectations, reaching $6 million vs. analysts' estimates of $5.6 million.

Aspect Medical Systems (ASPM), a maker of anesthesia-monitoring systems, sank 14.9% to $15.66, despite better-than-expected earnings in the second quarter. The company earned $2.1 million, or 9 cents a share, compared with $1.6 million, or 7 cents a share, last year.

Excluding stock-based compensation expenses, the company earned 16 cents a share, compared with analysts' expectations of 14 cents. Aspect's sales were up 21% to $22.6 million in the quarter.

The company's third-quarter guidance was lower than analysts were expecting, however. In its earnings report, the company said it expects to earn 14 cents to 16 cents a share on sales of $22 million to $22.8 million. Analysts surveyed by Thomson First call were expecting earnings of 16 cents a share in the third quarter on sales of $24.1 million.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ALNY $104.06 0.00%
BSX $17.83 0.00%
BVX $2.20 0.00%
HSTM $24.84 0.00%
AAPL $123.25 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs